Drug Profile
Trastuzumab biosimilar - Paras Biopharmaceuticals
Alternative Names: PB (CT)-4020Latest Information Update: 15 Jan 2022
Price :
$50
*
At a glance
- Originator Paras Biopharmaceuticals Finland
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB 2 receptor antagonists; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 28 Jun 2019 No recent reports of development identified for research development in Breast-cancer in Finland (Parenteral)
- 21 May 2015 Early research in Breast cancer in Finland (Parenteral) (Paras pipeline, May 2015)